PAR -v- CUV, page-63

Regardless of my post above - ignoring all other factors if you look at PAR against CUV on a market cap basis (which makes more sense than pure underlying share price. You will see CUV is 7x PAR market cap as of yesterday. Different addressable market size, different competition, different level of progress/success at this stage etc. probably makes it not that reasonable to use it as a like for like comparison on where PAR is may end up.

The quote from Fifty one Capital in comparing the two stocks is quoted below - there is not a lot mentioned on why they through CUV would be a good stock to use as a comparison.

"As an example, Clinuvel (ASX:CUV) is an Australian listed (as well as US & EU listed) biotech for the treatment of a very rare skin disease. Again, an indication that has an unmet need, but a much smaller comparable market than OA. Clinuvel has recently seen revenue grow to around $25m and expects to double this with upcoming potential FDA approvals. Their market cap is now A$1.25b. "



Just for transparency on where my conviction sits - I averaged down a little with another $5K at $1.34 yesterday. My avg. buy price now sits at $1.47.
I think PAR has higher market potential than AVH, whereas AVH is less speculative (more of a sure thing). Both are positions that at this stage I plan to hold for a few years or longer.